Marksans Pharma Consolidated September 2021 Net Sales at Rs 361.20 crore, up 1.33% Y-o-Y
NULL10-11-2021
Marksans Pharma Ltd - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants.
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended September 30, 2021 is given in "Annexure A".10-11-2021
Q2FY22 Quarterly Result Announced for Marksans Pharma Ltd.
Highlights: Consolidated Q2 FY22 (YoY): Operating Revenue was Rs. 361.2 Cr. as compared to Rs. 356.5 Cr. in Q2 FY21, an increase of 1.3% EBITDA was Rs. 60.1 Cr. as compared to Rs. 83.2 Cr. in Q2 FY21 EBITDA Margin stood at 16.6% as against 23.3% in Q2 FY21 PAT stood at Rs. 46.3 Cr. as compared to Rs. 50.7 Cr. in Q2 FY21 Consolidated H1 FY22 (YoY): Operating Revenue was Rs. 710.2 Cr. as compared to Rs. 687.6 Cr. in H1 FY21, an increase of 3.3% EBITDA was Rs. 137.4 Cr. as compared to Rs. 153.2 Cr. in H1 FY21 EBITDA Margin stood at 19.0% as against 22.2% in H1 FY21 PAT stood at Rs.108.9 Cr. as compared to Rs. 100.1 Cr. in H1 FY21, an increase of 8.8% Commenting on the performance Mark Saldanha, Managing Director of the Company said “We had a challenging half year with geopolitical issues impacting shipments and inputs. Our revenue growth of 3.3 percent in H1FY22 was driven by the increasing penetration in EU and North American markets. Higher raw material, freight and packaging costs impacted margins however reduced finance costs and lower tax outgo helped to neutralise the same resulting us grow our bottomline by 8.8% in H1FY22. We remain focused on delivering superior returns for the long term to all our stake holders.” Result PDF10-11-2021
Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Enclosed herewith kindly find a News Release dated 10th November, 2021 of the Company.10-11-2021
Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached an investors presentation of Marksans Pharma Limited for Q2 & H1 FY22.10-11-2021
Marksans Pharma Ltd - 524404 - Unaudited Financial Results For The Quarter And Half-Year Ended 30Th September, 2021 And Limited Review Reports Thereon
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half-year ended 30th September, 2021 which have been approved by the Board of Directors at its meeting held today i.e. 10th November, 2021 along with Limited Review Reports given by statutory auditor of the Company. The meeting commenced at 9:30 a.m. and concluded at 10:50 a.m.10-11-2021
Marksans Pharma Ltd - 524404 - Update on board meeting
The Board Meeting to be held on 09/11/2021 has been revised to 10/11/2021 This is reference to our intimation dated 26th October, 2021 in respect of the proposed board meeting scheduled to be held on 9th November, 2021 at Mumbai, inter alia, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and half year ended 30th September, 2021. Please be informed that the above board meeting has been re-scheduled to Wednesday, 10th November, 2021. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares has been closed for the Company's Designated Persons from 1st October, 2021 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on 10th November, 2021.27-10-2021
Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Notice Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2021 ,inter alia, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and half year ended 30th September, 2021. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company''s shares has been closed for the Company''s Designated Persons from 1st October, 2021 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on 9th November, 2021.26-10-2021
MARKSANS PHARMA LTD. - 524404 - Shareholding for the Period Ended September 30, 2021
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here13-10-2021